media – Page 44 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Brain pulsations driving glymphatic function differ in narcolepsy patients and healthy individuals

A hormone produced by the brain, orexin, may play a central role in the functioning of the brain’s glymphatic system, which clears waste, according to a new study from the University of Oulu. Published in the high-profile journal PNAS, the study examined how the pulsations driving the brain’s glymphatic clearance differ in people with narcolepsy type 1 compared with healthy individuals. For the first time, the research directly compared the brain pulsations of narcolepsy patients with those of healthy individuals during sleep. The study included 23 participants with narcolepsy type 1 and a group of healthy controls. Brain clearance involves three types of pulsation: cardiovascular pulsations generated by the heartbeat in the arteries, respiratory pulsations in the veins and cerebrospinal fluid spaces, and slow vasomotor waves in the walls of blood vessels. These pulsations, and the resulting brain clearance, are known to increase during sleep. Previous research has shown that ...
- Source: drugdu
- 107
- September 2, 2025
Alzheimer’s disease drug subcutaneous injection approved in the US

On August 29th local time, Japan’s Eisai Co., Ltd. and the US Biogen Inc. announced that the US FDA (U.S. Food and Drug Administration) has approved the weekly maintenance dose of lencanelumab subcutaneous automatic injection (SC-AI) for the treatment of early Alzheimer’s disease (AD). Comment: As of now, there are limited AD treatment drugs approved worldwide. This approval makes Lencaneluzumab the first AD treatment drug that can be administered subcutaneously at home using an automatic injector. The entire injection process takes an average of only 15 seconds, which further consolidates the company’s market position in this field. https://finance.eastmoney.com/a/202509013500390220.html
- Source: drugdu
- 104
- September 2, 2025
The new king of the multi-billion myeloma market is here

In the multi-billion dollar global myeloma market, BCMA/CD3 bispecific antibodies are becoming a powerful weapon reshaping the treatment landscape. Currently, the market is dominated by Johnson & Johnson, Pfizer, and Regeneron, with competition escalating. Digging for Gold in the Billion-Dollar Myeloma Market Multiple myeloma, a common hematologic malignancy, is experiencing an expanding global market for treatment. The market reached $28.3 billion in 2024 and is projected to continue growing at an average annual rate of 6.6%. Industry forecasts predict the market will exceed $52.1 billion by 2032. The global multiple myeloma market is currently characterized by a competitive landscape characterized by the simultaneous advancement of traditional drugs, biologics, and cell therapies. Forecast sales of key multiple myeloma therapeutics in major markets from 2024 to 2033 Image source: Nature reviews. Drug discovery, 24(4), 244–245. Among core therapeutic drugs, immunomodulators (IMiDs) still hold a significant position. Lenalidomide, a second-generation drug, continues to ...
- Source: drugdu
- 150
- September 2, 2025
Another breakthrough in overseas expansion! Henlius receives FDA approval for two osteoporosis treatment drugs

On September 1, Henlius Biopharmaceuticals (02696) announced that it had recently received approval from the U.S. Food and Drug Administration (FDA) for the development of two HLX14 (denosumab)-related products, BILDYOS® and BILPREVDA®.The license application was approved. These two products are used to treat osteoporosis and prevent bone-related events in specific populations, respectively. Specific indications include the treatment of osteoporosis in postmenopausal women and men, glucocorticoid-induced osteoporosis, and bone metastases in patients with multiple myeloma. https://finance.eastmoney.com/a/202509023502086989.html
- Source: drugdu
- 95
- September 2, 2025
How Platforms Are Reshaping Buyer–Supplier Collaboration

As the global pharmaceutical market continues to expand and cross-border e-commerce accelerates, efficiency has become the new priority in international trade. This article leverages market data and practical insights from Drugdu.com to examine how this shift is transforming the way buyers and suppliers collaborate. I. Global Trends: Pharmaceutical Trade on the Rise Sustained Market Growth: The global pharmaceutical market was valued at USD 1.65 trillion in 2024 and is projected to reach USD 2.35 trillion by 2030, growing at a CAGR of 6.1%. (Source: Grand View Research) Export Volume and Structural Shifts: In 2024, the value of global pharmaceutical exports reached approximately USD 1.8 trillion, with vaccines and oncology drugs accounting for 32% and 26%, respectively. (Source: Grand View Research) Europe also recorded significant growth, with pharmaceutical exports rising by 13.5% year-on-year in 2024 and its trade surplus expanding to EUR 194 billion. (Source: European Commission) II. The Rise of Cross-Border ...
- Source: drugdu
- 121
- September 2, 2025
HBME Wuhan

Organiser: China Council for the Promotion of International Trade Hubei Sub-Council, China Chamber of International Commerce Hubei Chamber of Commerce Time：March 13 – March 15, 2026 address：No. 696 Jiefang Avenue, Jianghan District, Wuhan City, Hubei Province Exhibition hall：Wuhan International Convention and Exhibition Center Product range: Diagnostic Equipment: Ultrasound diagnostic equipment, X-ray imaging diagnostic equipment, electrocardiogram (ECG) and encephalogram (EEG) monitoring equipment, image processing systems, scanning equipment, biochemical testing equipment, functional examination equipment, pathological diagnostic equipment, endoscopic examination equipment, patient monitors, optical instruments, and examination and diagnostic equipment for neurology, orthopedics, otolaryngology, ophthalmology, etc. Therapeutic Equipment: Surgical equipment for internal and external medicine, radiotherapy equipment, nuclear medicine treatment equipment, dialysis treatment equipment, radiofrequency treatment equipment, cryotherapy equipment, laser equipment, rehabilitation and physiotherapy equipment, emergency equipment, anesthesia and analgesia equipment, operating room equipment, surgical lights, operating tables, high-frequency electrosurgical units, etc., as well as dialysis treatment equipment, emergency equipment, anesthesia and ...
- Source: drugdu
- 215
- September 2, 2025
Babies fed blueberries show fewer allergy symptoms and boosted immune balance

In a recent study published in the journal Nutrients, researchers examined the impact of blueberry intake in early life on allergy-related symptoms, gut microbiota, and immune biomarkers. The complementary feeding period represents a critical time frame for shaping infant immune development, diet, and gut microbiota. Current recommendations suggest introducing a range of plant-based foods from six months of age, in conjunction with continued breastfeeding. Growing evidence supports a role for blueberries in the microbiota-inflammation-immunity axis and gut microbial homeostasis. The first year of life is a critical window for establishing immune competence and preventing allergic diseases. Dietary exposures during this period can influence the induction of immune tolerance, epigenetic programming, and gut microbial succession. Suboptimal or aberrant microbial colonization has been linked to increased gut permeability, impaired innate immune responses, and low-grade inflammation, all of which are associated with a higher risk of diseases in later life. About the study ...
- Source: drugdu
- 92
- September 1, 2025
First ESC statement on mental health and heart disease promotes integrated care

A new ESC Clinical Consensus Statement is calling for greater awareness of the multidirectional relationship between mental health conditions and cardiovascular disease to improve patient health. The first ever ESC Clinical Consensus Statement to be developed on this topic was published today at ESC Congress 2025. The Consensus Statement recommends that mental health symptoms are systematically screened for during cardiovascular care, and cardiovascular risk is routinely assessed for those being treated for mental health conditions. While poor mental health can be a contributory factor to cardiovascular disease, people living with cardiovascular disease are also at greater risk of poor mental health. Patients experiencing both cardiovascular disease and a mental health condition have worse health outcomes. The Consensus Statement has been produced by an international panel of experts that includes co-Chairpersons Professor Héctor Bueno, from the National Cardiovascular Research Center (CNIC) and the Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, ...
- Source: drugdu
- 99
- September 1, 2025
Another Phase III clinical study of Tetasip is successful

On August 27, Rongchang Biopharma announced that its independently developed world’s first BLyS/APRIL dual-target fusion protein innovative drug Taitasip (trade name: Tai Ai®) for the treatment of primary immunoglobulin A (IgA) nephropathy reached the primary study endpoint of Phase A in the domestic Phase III clinical study. Study results showed that compared with the placebo group, patients in the tetasip group experienced a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at week 39 of treatment (P<0.0001), demonstrating good tolerability and safety. Rongchang Biopharma stated that it will submit a marketing application to the National Medical Products Administration (NMPA) as soon as possible, and detailed data will be presented at a major international academic conference. This multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial enrolled 318 adult patients with IgA nephropathy receiving standard treatment. Tetasipir was administered at a dose of 240 mg subcutaneously once weekly. The study aimed to ...
- Source: drugdu
- 100
- September 1, 2025
A world first! Sino Biopharmaceutical’s oral targeted drug, Sanhetu, for advanced non-small cell lung cancer with HER2 mutations has been approved

On August 29, Boehringer Ingelheim and Sino Biopharmaceutical (01177.HK) jointly announced that their jointly promoted drug, Zongertinib (Chinese generic name: Zongertinib tablets, English generic name: zongertinib), has been officially approved by the China National Medical Products Administration for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating HER2 (ERBB2) mutations and have received at least one previous systemic therapy. Sanhetu® is the world’s first and currently only approved oral HER2 tyrosine kinase inhibitor. Its conditional approval in China is based on positive results from the Beamion-LUNG 1 study, which evaluated the efficacy and safety of zonectinib in patients with advanced non-small cell lung cancer (NSCLC) harboring a HER2 (ERBB2) mutation. Data from cohort 1 (N=75) of previously treated patients demonstrated an objective response rate (ORR) of 71% (95% CI: 60-80), including 7% complete responses, and a disease control rate (DCR) ...
- Source: drugdu
- 91
- September 1, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.